Biotech Values

[NP1986]

Isn't the QTc issue a huge red flag? I have osteoarthritis and I'm not sure I'd want to take this drug and ARRY is my second biggest holding. LOLOL The SP is down 12% in AH. (I really think this might be overdone; no one that I know had this drug factored into their valuation models.) Would any BP want to take on this drug?

I agree that the QTc issue is concerning, unless they want to target a niche population (e.g. acute use in patients who cannot tolerate oxycodone). I think it will make potential partners think twice about licensing ARRY-797 because cardiovascular issues are bound to be a huge concern for chronic use.